Recludix Pharma Takes Center Stage at JPM With Novel Inflammation Drugs

SAN DIEGO, CA – January 07, 2026 – Recludix Pharma, a clinical-stage biotech company recognized for its innovative approach to complex drug targets, is set to capture the industry's attention next week. The company announced that its President and CEO, Nancy Whiting, Pharm.D., will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, a premier event for investors and pharmaceutical leaders.

The presentation, scheduled for January 15, comes at a pivotal moment for the San Diego-based firm. Having been named one of Fierce Biotech's "Fierce 15" of 2024, Recludix is riding a wave of momentum, bolstered by a blockbuster partnership with Sanofi and the recent advancement of its lead drug candidate into Phase 1 clinical trials. The company's appearance at the influential conference signals its readiness to showcase the progress of its unique drug discovery engine, which aims to produce medicines for targets long considered "undruggable."

From 'Fierce 15' to the JPM Spotlight

For a privately held, clinical-stage company like Recludix, an invitation to present at the J.P. Morgan conference is a significant milestone. The event is the unofficial starting bell for the year in biotech, where strategic partnerships are forged, investment deals are initiated, and a company's trajectory can be fundamentally altered. Recludix, which launched in 2021 with a $60 million Series A round led by prominent investors including New Enterprise Associates (NEA) and Westlake Village BioPartners, will use this platform to detail its strategy and pipeline progress to a global audience.

The company's profile was significantly elevated in 2024 when it was named to the prestigious "Fierce 15" list, an annual honor roll of the most promising private biotechs. The recognition lauded Recludix for its success in drugging SH2 domains, a notoriously difficult class of protein targets, and validated the platform that secured its landmark collaboration with pharmaceutical giant Sanofi. This upcoming presentation is the next logical step, moving from industry accolade to a direct appeal to the financial and strategic heart of the healthcare sector.

Cracking the Code of "Undruggable" Targets

At the core of Recludix's story is its proprietary drug discovery platform, an integrated system designed to overcome historical challenges in medicinal chemistry. The company has focused its initial efforts on Src Homology 2 (SH2) domains, which are critical signaling nodes within cells but have resisted drug development efforts for decades due to their shallow binding pockets and complex interaction mechanisms.

Recludix's multi-pronged approach combines several cutting-edge technologies. It begins with custom-designed DNA-encoded libraries (DELs), which allow for the screening of billions of molecules simultaneously against a target. Unlike conventional methods, Recludix's platform enables the rapid determination of structure-activity relationships (SAR) directly from these massive screens. This process is further accelerated by high-resolution crystallography and a unique, proprietary screening tool that assesses a compound's selectivity across more than 75% of the entire human SH2 domain family. This ensures that any potential drug candidate is not only potent but also highly specific, a key factor in minimizing off-target side effects.

This technological engine has produced the company's two lead programs, both of which target SH2 domains. The first, a STAT6 inhibitor, is now in the clinic, while the second, a BTK inhibitor, is advancing in preclinical studies, demonstrating the platform's potential to generate a pipeline of first-in-class therapies.

Sanofi's Billion-Dollar Bet on an Oral Successor to Dupixent

The most significant validation of Recludix's platform came in July 2023 with the announcement of a strategic partnership with Sanofi. The collaboration is focused on developing oral STAT6 inhibitors, with Recludix’s lead asset, REX-8756 (now also known as SAR448755), at its center. STAT6 is a key driver of type 2 inflammation, the underlying cause of a range of debilitating conditions including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD).

The financial terms of the deal underscore the potential Sanofi sees in the program. Recludix received $125 million in near-term payments and is eligible for over $1.2 billion in development, regulatory, and sales milestones. The agreement also includes tiered royalties and a compelling option for Recludix to participate in an equal U.S. profit-and-loss sharing arrangement.

This partnership is particularly strategic for Sanofi, which co-markets Dupixent, a blockbuster injectable antibody that also targets the type 2 inflammation pathway. An effective, safe, and convenient oral therapy like REX-8756 could be a game-changer, potentially capturing a significant portion of a market currently dominated by biologics. For Recludix, the deal provided a substantial non-dilutive capital infusion and the expertise of a global pharmaceutical leader to guide the drug through late-stage development and commercialization. Following the FDA's clearance of its Investigational New Drug (IND) application in December 2025, Recludix has now initiated a Phase 1 study of REX-8756, a critical step forward for the partnership.

Navigating a Competitive Inflammatory Disease Landscape

While Recludix’s technology is novel, it is entering a highly competitive therapeutic area. The market for type 2 inflammatory diseases is crowded with effective, albeit often injectable, treatments like Dupixent. The race for a potent and safe oral alternative is heating up. Competitors include broad-acting oral JAK inhibitors, which have shown efficacy but carry safety warnings that have limited their use.

More direct competition is emerging from companies also targeting STAT6. Kymera Therapeutics is advancing an oral STAT6 degrader, which works by destroying the protein rather than inhibiting it, and has already entered human trials. Enanta Pharmaceuticals is also developing a STAT6 inhibitor, with plans to file for an IND later this year. Recludix's differentiation lies in its specific mechanism—inhibiting the STAT6 SH2 domain—which it believes will offer a best-in-class safety and efficacy profile.

Beyond STAT6, Recludix is advancing a potential first-in-class BTK SH2 domain inhibitor for diseases like chronic spontaneous urticaria (CSU). This field also saw recent progress with Novartis gaining FDA approval for its oral BTK inhibitor, remibrutinib, for CSU in late 2025. However, by targeting the BTK protein's SH2 domain instead of its kinase domain, Recludix hopes to achieve superior selectivity and sustained inhibition, carving out a unique position in the market. As the company prepares to present its progress, all eyes will be on any new data that could further distinguish its candidates from the growing field of competitors.